A Study on Hemolytic Disease of the Fetus and Newborn (HDFN) Through Global Registry

Key facts

Sponsor

Janssen Research & Development, LLC

Principal Investigator

Janssen Research & Development, LLC Clinical Trial

Janssen Research & Development, LLC

Intervention

Standard of Care(other)

Enrollment

175 enrolled

Eligibility

18 years · FEMALE

Timeline

2025 – 2030

Study locations (10)

• Riley Children s Hospital, Indianapolis, Indiana, United States
• University of Cincinnati, Cincinnati, Ohio, United States
• Oregon Health And Science University, Portland, Oregon, United States
• Baylor College of Medicine, Houston, Texas, United States
• The Royal Women's Hospital, Parkville, Australia
• Mater Misericordiae Ltd, South Brisbane, Australia
• Interdiszip Schwerpunkt fur Hamostaseologie, Giessen, Germany
• Mangiagalli Clinic IRCCS Ca Granda Foundation Ospedale Maggiore Policlinico, Milan, Italy
• Fondazione Policlinico Universitario A Gemelli IRCCS, Roma, Italy
• Birmingham Women's Hospital, Birmingham, United Kingdom

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Other trials for Hemolytic disease due to fetomaternal alloimmunization

Additional recruiting or active studies for the same condition.

• RECRUITINGNCT06984445
  Cord Blood S100B Protein Levels in Neonates Following Intrauterine Transfusions for HDFN-Associated Fetal Anemia
  Institute of Mother and Child, Warsaw, Poland
• RECRUITINGPHASE3NCT05912517
  A Study of Nipocalimab in Pregnancies at Risk for Severe Hemolytic Disease of the Fetus and Newborn (HDFN)
  Janssen Research & Development, LLC

See all trials for Hemolytic disease due to fetomaternal alloimmunization →